Home›Stock Screener›Beta Drugs›Quarterly Results

Beta Drugs Quarterly Results

Latest Quarter Net Profit
₹9 Cr
QMar 2026
Quarterly Results

Beta Drugs quarterly results. In Mar 2026, Beta Drugs (BETA) reported revenue ₹97 Cr and net profit ₹9 Cr — revenue -1.0% YoY. Review Beta Drugs price earnings to evaluate earnings-based valuation against sector peers.

BETA Quarterly Results — Revenue, Profit & EPS Highlights

Beta Drugs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Beta Drugs screener.

  • Revenue of ₹97 Cr in Mar 2026 (-23.6% vs Jun 2026, -1.0% vs Mar 2025)
  • Net Profit of ₹9 Cr in Mar 2026 (-47.1% vs Jun 2026, +0.0% vs Mar 2025)
  • EBITDA of ₹21 Cr in Mar 2026 (-27.6% vs Jun 2026)
  • Operating Margin of 19.0% in Mar 2026 (-3.0pp vs Jun 2026)
  • Earnings Per Share of ₹8.93 in Mar 2026 (-39.6% vs Jun 2026)

Beta Drugs Quarterly Results — Revenue, EBITDA, Net Profit & EPS

BETA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 97 127 106 98 103 -23.6% -1.0%
Net Profit (₹ Cr) 9 17 12 9 12 - -
EBITDA (₹ Cr) 21 29 24 19 23 - -
EPS (₹) 8.93 14.78 12.10 9.40 11.59 - -
Operating Margin (%) 19.0% 22.0% 21.0% 16.0% 20.0% - -

BETA Share Price Trend — 1-Year Movement Across Quarterly Results

Beta Drugs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check BETA company valuation to track the company's total market size over time.

Profitability Ratios

Profit Margin 9.3%
EBITDA Margin 21.6%
Operating Margin 19.0%
ROE (Annual) 14.7%

Balance Sheet Highlights

Total Assets ₹496 Cr
Total Equity ₹245 Cr
Current Assets ₹335 Cr
Current Liabilities ₹143 Cr

Cash Flow Analysis

Operating Cash Flow ₹36 Cr
Investing Cash Flow ₹-36 Cr
Financing Cash Flow ₹118 Cr
Net Cash Flow ₹118 Cr

Current Market Data

Current Price ₹2004.00
Exchange NSE
Last Updated Oct 05, 2026

Revenue Trend (₹ Cr)

Mar 2025 98
Sept 2025 106
Jun 2026 127
Mar 2026 97

Net Profit Trend (₹ Cr)

Mar 2025 9
Sept 2025 12
Jun 2026 17
Mar 2026 9

Operating Margin Trend (%)

Mar 2025 16.0%
Sept 2025 21.0%
Jun 2026 22.0%
Mar 2026 19.0%

BETA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Beta Drugs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹432,120.23 Cr 1779.7 15,018 2,710 -5.6% - 18.0% 157.5
Divis Laboratories
Mar 2026 		₹244,124.91 Cr 9196.0 2,986 751 -5.0% - 25.2% 324.8
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4772.0 4,111 364 +27.7% +42.2% 8.9% 414.6
Zydus Life Science
Mar 2026 		₹113,615.69 Cr 1139.0 7,569 1,341 -4.3% - 17.7% 90.0
Cipla
Mar 2026 		₹108,576.18 Cr 1335.5 6,612 543 -9.3% - 8.2% 194.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores